primary antibodies against cd68 (R&D Systems)
Structured Review

Primary Antibodies Against Cd68, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary antibodies against cd68/product/R&D Systems
Average 93 stars, based on 13 article reviews
Images
1) Product Images from "Discovery of ETI41 and ETI60: novel selective endosomal Toll-like receptor inhibitors for the treatment of autoimmune diseases"
Article Title: Discovery of ETI41 and ETI60: novel selective endosomal Toll-like receptor inhibitors for the treatment of autoimmune diseases
Journal: Experimental & Molecular Medicine
doi: 10.1038/s12276-025-01526-w
Figure Legend Snippet: a Psoriasis was induced in female C57BL/6J mice by topically applying IMQ (62.5 mg/cm 2 ). ETI41 and ETI60 were orally administered daily at a dose of 60 mg/kg. b Impact of ETI41 and ETI60 on body weight during treatment. c PASI score indicating disease severity. d Images of the back skin of mice were captured on the fifth day of treatment, revealing the therapeutic efficacy of ETI41 or ETI60 compared with the normal and untreated groups. Immunohistochemical staining of back skin sections from each group revealed the effects of ETI41 and ETI60 on thickness of the epidermis (yellow arrowhead) and dermis (green arrowhead). e The thickness of the epidermis and dermis, as well as the expression levels of CD68 (a macrophage marker), Ki-67, IL-17A and IL-23, were measured. f Psoriasis was induced in female C57BL/6J mice by injecting IL-23 (500 ng) into their ear skin. Anti-IL17A antibody (Ab, 60 µg) was administered by IP injection as a positive control on days 2, 5 and 8. ETI41 or ETI60 was administered orally at a daily dose of 60 mg/kg for 9 days. g Body weight was recorded during treatment. h On the ninth day of treatment, images of the mouse ears were acquired to demonstrate the therapeutic efficacy of ETI41 and ETI60 in comparison with the normal, vehicle or anti-IL17 groups. CD68 and Ki-67 expression patterns were determined in skin sections from a representative of each group using immunofluorescence. i Ear skin and epidermis thickness, CD68 expression and percentage of Ki-67 cells were examined from 4’,6-diamidino-2-phenylindole-stained cells. Statistical differences between the induced case and other cases were analyzed and verified using a one-tailed Student’s t -test (* P < 0.05, ** P < 0.01, *** P < 0.001).
Techniques Used: Drug discovery, Immunohistochemical staining, Staining, Expressing, Marker, Injection, Positive Control, Comparison, Immunofluorescence, One-tailed Test
